|
gptkbp:instanceOf
|
recreational drug
|
|
gptkbp:alsoKnownAs
|
gptkb:Molly
gptkb:Ecstasy
gptkb:3,4-methylenedioxymethamphetamine
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:ATCCode
|
N06BX13
|
|
gptkbp:chemicalFormula
|
C11H15NO2
|
|
gptkbp:color
|
white
|
|
gptkbp:controlledBy
|
gptkb:DEA
gptkb:UN_Convention_on_Psychotropic_Substances
|
|
gptkbp:discoveredBy
|
gptkb:Anton_Köllisch
|
|
gptkbp:discoveredIn
|
1912
|
|
gptkbp:effect
|
euphoria
increased empathy
enhanced sensations
|
|
gptkbp:eliminationHalfLife
|
7–9 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MDMA
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
illegal in most countries
|
|
gptkbp:MeSH_ID
|
D008628
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
193.25 g/mol
|
|
gptkbp:parent
|
amphetamine
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL402
1554
1615
|
|
gptkbp:relatedTo
|
gptkb:MDA
amphetamine
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
addiction
hyponatremia
neurotoxicity
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:sideEffect
|
anxiety
dehydration
insomnia
hyperthermia
jaw clenching
depression (after use)
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:streetForm
|
gptkb:tablet
capsule
powder
|
|
gptkbp:UNII
|
J1DOI7UV76
|
|
gptkbp:usedFor
|
gptkb:psychotherapy
recreational purposes
|
|
gptkbp:usedIn
|
clinical trials for PTSD
|
|
gptkbp:bfsParent
|
gptkb:Molly
gptkb:MAPS
gptkb:Acid_Test:_LSD,_Ecstasy,_and_the_Power_to_Heal
|
|
gptkbp:bfsLayer
|
5
|